title: MCA in patients with breast cancer: correlation with CEA and CA15-3.
abstract: MCA serum levels were determined in 27 healthy subjects, 136 with benign pathology (42 breast) and in 289 patients with cancer (247 active). The last group includes 223 patients with breast cancer (96 without metastases, 89 with metastases and 38 no-evidence of disease). CEA and CA15-3 serum levels were determined in all the patients with breast diseases. The mean levels of MCA were 4.7 + 2.4 U/ml in the control group, considering less than 11 U/ml as normal. MCA values were abnormal in 15.4% of patients with benign pathology, mainly in those with liver cirrhosis (8/20) and lung diseases (4/20). In the majority of these cases, the rise was only moderate, lower than 15 U/ml in 97.5% of patients. In malignant diseases, important increments were found in breast cancer (19.8% Mo, 77.5% M1) and ovarian cancer stages III-IV (44.4%). When we compared MCA serum levels with CA15-3 and CEA in breast pathology, a similar specificity was observed: 92.3%, 92.3% and 100% in cases with benign pathology and 92.1%, 94.7%, and 97.4% in NED patients, respectively. MCA and CA15-3 sensitivity was similar in breast cancer without metastases (19.8%) and lower for CEA (16.7%). In patients with breast cancer without metastases, we found a relation between positivity of these tumor markers and prognostic factors (tumor size, nodal involvement). The disease free interval in patients with locoregional breast cancer was shorter in cases with abnormal presurgical levels of some of the tumor markers, but only the difference from MCA was significant (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratory of Clinical Biochemistry (Unit for Cancer Research), School of Medicine, Hospital Clinico, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Molina
authors.forename: X
authors.initials: X
authors.lastname: Filella
authors.forename: P
authors.initials: P
authors.lastname: Mengual
authors.forename: M
authors.initials: M
authors.lastname: Prats
authors.forename: G
authors.initials: G
authors.lastname: Zanon
authors.forename: M
authors.initials: M
authors.lastname: Daniels
authors.forename: A M
authors.initials: AM
authors.lastname: Ballesta
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000097:blood*; D016009:Chi-Square Distribution; D015179:Colorectal Neoplasms / Q000097:blood; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000097:blood; D008297:Male; D010051:Ovarian Neoplasms / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood
chemical_list: D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; C057387:mucinous carcinoma-associated antigen